Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Computer-tailored drug dosing aims to tame Crohn's in kids

NCT ID NCT04974099

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tested whether a computer program that customizes infliximab doses based on blood tests can help children and young adults with Crohn's disease reach better drug levels than standard dosing. Only 6 participants were enrolled before the study was stopped early. The goal was to see if personalized dosing is feasible and safe, not to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
infliximab
What this could lead to
If successful, this could show that personalized dosing helps more patients reach optimal drug levels, potentially improving disease control.
What could go wrong
This was a small, terminated early study with only 6 participants, so results are very limited and may not apply broadly. The approach may not prove better than standard dosing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

6 people

The number who actually took part.

Started

Oct 2021

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 22 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent form from the patient (≥18 years old) or from parent/legal guardian if patient is \<18 years old. 2. Written informed assent form from patient ≥11 years old. 3. Age criteria: ≥6 years to ≤22 years of age. 4. Diagnosis of Crohn's Disease 5. Starting infliximab (or biosimilar) 6. Anti-TNF naïve (never received infliximab, adalimumab, golimumab, certolizumab or anti-TNF biosimilar) 7. Fecal calprotectin \>250 µg/g or fecal lactoferrin \>10 µg/g (up to 6 weeks prior to starting infliximab) or endoscopic evidence of active Crohn's disease (up to 90 days prior to starting infliximab) 8. wPCDAI \>12.5 (up to 6 weeks) prior to the first infliximab infusion 9. Negative urine pregnancy test for ALL female subjects 10. Negative TB (tuberculosis) blood test Exclusion Criteria: 1. Diagnosis of ulcerative colitis or inflammatory bowel disease-unspecified 2. Prior treatment with infliximab, adalimumab, certolizumab or golimumab (or anti-TNF biosimilar) 3. Active or prior evidence in past 12 months of internal (abdominal/pelvic) penetrating fistula(e) 4. Active intestinal stricture (luminal narrowing with pre-stenotic dilation \>3mm), intra-abdominal abscess or perianal abscess 5. Active Clostridium difficile infection or other known bacterial/viral gastroenteritis in last two weeks 6. Current ileostomy, colostomy, ileoanal pouch, and/or previous extensive small bowel resection leading to short bowel syndrome 7. History of autoimmune disease (including autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis) 8. Treatment with another investigational drug within four weeks. 9. Treatment with intravenous antibiotics within four weeks. 10. Planned continuation of 6-mercaptopurine or azathioprine (Imuran) during study. 11. Planned continuation of methotrexate during study. 12. Treatment with intravenous corticosteroids within two weeks. 13. Currently pregnant, breast feeding or plans in next 12 months to become pregnant 14. Inability or failure to provide informed assent/consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cincinnati Children's Hospital

    Cincinnati, Ohio, 45229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.